Results 21 to 30 of about 1,998,403 (289)

Cardiotoxicity of Immune Checkpoint Inhibitors [PDF]

open access: yesCurrent Oncology Reports, 2021
Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression, cardiovascular toxicity can be associated with high rates of morbidity and mortality.
Rushin P. Patel   +6 more
openaire   +2 more sources

Immune checkpoint inhibitors in malignancy [PDF]

open access: yesAustralian Prescriber, 2019
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire   +2 more sources

Immune Checkpoint Inhibitors and Neurotoxicity

open access: yesCurrent Neuropharmacology, 2021
: Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with ...
Zhao, Zhiyi   +4 more
openaire   +3 more sources

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0

open access: yes, 2022
Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies.
Andréia Cristina de Melo   +22 more
core   +1 more source

The role of immune checkpoint inhibitors in prostate cancer [PDF]

open access: yes, 2018
Introduction Prostate cancer (PC) is the most commonly diagnosed malignant tumour and the third cause of cancer deaths among men in Europe. The treatment of early-stage PC is very effective and in many cases allows achievement of a complete cure, whereas
Marek Hus   +9 more
core   +1 more source

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

open access: yesCancer Biology & Medicine, 2015
Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis   +2 more
doaj   +1 more source

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors

open access: yesZhongliu Fangzhi Yanjiu, 2021
Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers.
YU Lin   +3 more
doaj   +1 more source

Immune Checkpoint Inhibitors in NSCLC [PDF]

open access: yesCurrent Treatment Options in Oncology, 2014
Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong survival, however, the median survival for patients with metastatic disease remains poor and more effective therapies are needed.
Douglas B, Johnson   +2 more
openaire   +2 more sources

Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients

open access: yesKidney International Reports, 2020
Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients.
Sandhya Manohar   +4 more
doaj   +1 more source

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

open access: yesJournal of Immunology Research, 2020
Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy